Drug Research
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Amgen and Arrowhead Pharmaceuticals Inc announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. ...
Drug Research
Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with viratherapeutics
Boehringer Ingelheim and ViraTherapeutics announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate Vira Therapeutic’s lead...
Drug Research
Catalent Showcases Advanced Formulations, Development Technologies And Drug Delivery Solutions At CPhI Worldwide
Catalent Pharma Solutions (Booth 3J16), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced a...
Drug Research
Bayer and Forschungszentrum Juelich agree on research collaboration
At the signing ceremony of the new research collaboration: Back row from left: Dr. Simone Gatzke, Forschungszentrum Juelich, Raphael Dumain, Dr. Isolde Häuser-Hahn and Dr....
Drug Research
GSK presents positive results from phase III FULFIL study at ERS International Congress
GlaxoSmithKline plc and Innoviva, Inc announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone...
Drug Research
Boehringer Ingelheim enters research agreement with Saniona
Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, announced...
Drug Research
Nymox Pharmaceutical Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results
Nymox Pharmaceutical Corp is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.